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Glaucomaisaheterogeneousgroupofdisordersthatprogressivelyleadtoblindnessduetolossofretinalganglioncellsanddamage
totheopticnerve.Itisaleadingcauseofblindnessandvisualimpairmentworldwide.Althoughresearchintheﬁeldofglaucoma is
substantial, the pathophysiologic mechanisms causing the disease are not completely understood. A wide variety of animal models
have been used to study glaucoma. These include monkeys, dogs, cats, rodents, and several other species. Although these models
have provided valuable information about the disease, there is still no ideal model for studying glaucoma due to its complexity. In
this paper we present a summary of most of the animal models that have been developed and used for the study of the diﬀerent
types of glaucoma, the strengths and limitations associated with each species use, and some potential criteria to develop a suitable
model.
1.Introduction
Glaucoma is a leading cause of blindness and visual impair-
ment worldwide aﬀecting 70 million people [1]. It is a
devastating disorder that leads to retinal ganglion cell (RGC)
degeneration, visual ﬁeld loss, and, eventually, blindness. To
date, over 3 million Americans suﬀer from glaucoma, with
another 100,000 patients being diagnosed each year [1, 2].
Although eﬀorts and research in the ﬁeld of glaucoma are
substantial, its pathophysiology is not completely under-
stood.
Animalmodelshavegreatlyimprovedourunderstanding
of the causes and progression of human diseases and have
proven to be a useful tool for discovering targets for ther-
apeutic drugs. However, several diseases remain incurable
because not all models used for studying these diseases
mimicked the human disorders completely.
In glaucoma, a wide variety of animal models of diﬀerent
species have been used to study the disease [3, 4]. These
included large animals such as monkeys [5], dogs and cats
[6, 7], pigs [8], and small animals such as rodents [9]. Glau-
coma in these animals was either spontaneous or induced.
Although these models have provided valuable information
about the disease, they all had drawbacks and glaucoma
remains incurable.
Several types of glaucoma have been described. These
have been broadly classiﬁed as acute and chronic, secondary
and primary. In general, glaucoma in humans is classiﬁed
into three major types: Primary Open Angle Glaucoma
(POAG), Primary Angle Closure Glaucoma (PACG), and
Primary Congenital Glaucoma (PCG) with POAG being the
most common type in most populations [10]. Although
the ﬁnal common pathway of tissue damage in all types of
glaucoma is the axonal damage that manifests as optic nerve
(ON) atrophy, causing progressive visual ﬁeld defects that
eventually lead to blindness, each type of glaucoma may
be caused by a diﬀerent mechanism. Elevated intraocular
pressure(IOP)isacommonthreadthatconnectsmostforms
of glaucoma and is a major risk factor for the disease. In this
paper, we describe a wide variety of the animal species that
have been developed and used to study the diﬀerent types
of glaucoma and outline their features, unique strengths and
limitations, as well as some potential criteria to develop a
suitable model.2 Journal of Biomedicine and Biotechnology
Table 1: Summary of the animal models commonly used for glaucoma research.
Glaucoma type Animal Model mode, mechanism Reference
POAG
Monkey
Spontaneous inheritance [11]
Laser photocoagulation of entire TM, reduced outﬂow by PAS [12–17]
Intracameral injection of latex microspheres, TM blockage [18]
Intracameral injection of autologous ﬁxed red blood cells, TM blockage [19, 20]
Dog Spontaneous inheritance [21, 22]
Mouse Transgenic, Myoc mutation [23, 24]
Transgenic, alpha-1 subunit of collagen type I [25, 26]
Rat Topical application of dexamethasone [27]
Zebraﬁsh
Transgenic, bug eye mutant [28, 29]
Transgenic, Irp2 mutation [30]
Transgenic, wdr36 mutation [31]
Rabbit Subconjunctival injection of betamethasone [32–34]
Posterior chamber injection of α-chymotrypsin, TM blockage [35–37]
Sheep Topical application of prednisolone [38–40]
Cow Topical application of prednisolone [41, 42]
Birds Light-induced, reduced outﬂow facility [43–45]
PACG
Dog Spontaneous inheritance [46–53]
Turkey Spontaneous inheritance [54]
Rat
Episcleral vein injection of saline, obstruction of outﬂow [55]
Injection of polystyrene microbeads or hyaluronic acid, TM blockage [56, 57]
Cauterization of episcleral veins, reduced outﬂow by PAS [58]
Ligation of episcleral veins, obstruction of outﬂow [59]
Laser photocoagulation of translimbal region, reduced outﬂow by PAS [60]
Mouse
Transgenic, Vav2/Vav3 knockout [61]
Laser photocoagulation of episcleral veins, reduced outﬂow by PAS [62, 63]
Cauterization of episcleral veins, reduced outﬂow by PAS [64]
Rabbit Water loading, decreased outﬂow facility [65, 66]
Laser photocoagulation of TM, obstruction of outﬂow [67–69]
PCG
Rabbit Spontaneous inheritance [70–75]
Rat Spontaneous inheritance, WAG strain [76, 77]
Spontaneous inheritance, RCS strain [78, 79]
Cat Spontaneous inheritance [6, 21, 80, 81]
Mouse Transgenic, Cyp1b1 mutation [82–84]
Transgenic, Cyp1b1 and Tyr mutations [85]
Quail Spontaneous inheritance, al mutant [86, 87]
Normal tension Mouse Transgenic, Glast or Eaac1 mutation [88]
Autoimmune Rat Immunization against HSP27 and HSP60, RGC loss [89, 90]
Pigmentary Mouse DBA/2J strain, Gpnmb, and Tyrp1 mutation [91–93]
TM: trabecular meshwork; PAS: peripheral anterior synechiae; RGC: retinal ganglion cell.
1.1. Primary Open Angle Glaucoma (POAG). POAG is the
most common form of glaucoma in most populations. More
than 20 genetic loci have been reported for POAG but only
three causative genes have been identiﬁed to date (Myocilin,
Optineurin, and WDR36) [94]. POAG is characterized by
elevated IOP and acquired loss of RGCs and atrophy of
the ON [10]. Animal models (spontaneous and induced)
that have been used to study POAG (Table 1), and provided
valuable information about the disease are described below.
1.1.1. Monkeys. Glaucoma in monkeys was ﬁrst described in
1993, when a group of rhesus monkeys at the Cayo Santiago
monkey colony in Puerto Rico examined for potential dis-
eases in the posterior segment of the eye were found to have
both low and high (> or =22mmHg) tension POAG [11].
POAG in the rhesus monkey was found to be of maternal
inheritance in more than 40% of the animals demonstrating
increased IOP. Aﬀected animals exhibit a loss of RGCs,
excavation of the ON, and electrophysiological evidence of
damage to the retinal peripheral ﬁeld.
Experimental monkey models have also been developed
for the study of POAG. Gaasterland and Kupfer developed
an experimental monkey model using argon laser pho-
tocoagulation [12]. They used a modiﬁed Koeppe-typeJournal of Biomedicine and Biotechnology 3
goniolens to laser the entire circumference of the trabecular
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the animals. The IOP range was between 24 and 50mmHg
after the 4th treatment and remained elevated for 25 days.
Histopathologic specimens from eyes with elevated IOP and
ON cupping showed selective loss of RGCs and thinning
of the nerve ﬁber layer compared with specimens from
untreated controls suggesting that glaucoma was achieved.
Several studies after that used the monkey model to describe
the functional and anatomic changes that occur within the
eyeandONinaneﬀorttounderstandthereasonsthatleadto
elevatedIOP[13–17].Otherexperimentalmonkeymodelsof
chronic IOP elevation were developed by Weber and Zelenak
usinglatexmicrospheres[18]andQuigleyandAddicksusing
autologous ﬁxed red blood cells [19, 20]. Another model that
develops acute elevation of IOP was also used to study the
mechanism of ON damage [95].
The close phylogeny and high homology of the monkey
with humans makes it an excellent model for studying
glaucoma. Monkeys have retinal and ON anatomy that is
almostidenticaltohumans.Unfortunately,monkeysarevery
expensive, their availability is limited, and they are diﬃcult
to handle. Experiments using monkeys require highly expe-
rienced teams and special housing facilities, making them
beyond the reach of many research laboratories.
1.1.2. Dogs. In 1981, Gelatt et al. described an inherited
POAG in the beagles bred in their laboratory [21]. The con-
dition appeared to be autosomal recessive. Elevation of IOP
(30 to 40mmHg) in this model developed bilaterally at 1-2
years of age, tonographic recordings, and constant pressure
perfusions indicated a reduction in the aqueous humor
outﬂow. Gonioscopically, the disease had two phases: open
iridocorneal angle during the onset and the ﬁrst 2–4 years
of the disease and closed iridocorneal angles associated with
lenssubluxationanddisplacementfromtheanteriorvitreous
patellarfossa.Theanimalalsoexhibitedcuppingandatrophy
of the optic disc, buphthalmia, cataract formation, vitreous
syneresis, and eventually phthisis bulbi. This model was
recently used in a genome wide SNP array study to map the
disease genes and led to the identiﬁcation of the metallopro-
teinase ADAMTS10 as a candidate gene for POAG [22].
The advantage of using this model and dogs in general
in glaucoma research is the spontaneous inheritance of the
disease without congenital anomalies and the availability of
the genome sequence. Dogs have relatively large eyes but can
be aggressive and diﬃcult to handle in the laboratory. Also,
anatomically, dogs have an intrascleral plexus, rather than a
Schlemm’s canal; this diﬀerence may be minor but can be a
limitation and their availability may be limited.
1.1.3. Mice. A mouse strain expressing the Tyr423His my-
ocilin point mutation corresponding to the human MYOC
Tyr437His mutation was developed to study POAG [23, 24].
Myocilin is one of the causative genes of POAG in humans
[96] and has been extensively studied. At 18 months of age,
the myocilin model demonstrated loss of ∼20% of the RGCs
in the peripheral retina, axonal degeneration in the ON,
detachment of the endothelial cells of the trabecular mesh-
work (TM), and moderate and persistent elevation of IOP
(2mmHg higher than normal) [23].
Another transgenic mouse strain with a targeted muta-
tion in the gene for the α1 subunit of collagen type I has also
been developed to study POAG. This model demonstrated
open angles, progressive ON axonal loss, and gradual eleva-
tionofIOPsuggestinganassociationbetweenIOPregulation
and ﬁbrillar collagen turnover [25, 26].
There are several advantages of using mice in glaucoma
research. These include the high degree of conservation
between mice and human genomes, enabling genetic manip-
ulation by altering the mouse genome, and the ability to
breed the animals as desired. In addition, they are inex-
pensive and easy to house and handle, their eyes are easy to
obtain, and the sample number for studies can be large. The
disadvantages of the mouse model in glaucoma are the
absence of the lamina cribrosa in the ON, the very small size
of the globe which makes it hard to access clinically, and the
availability of speciﬁc models may be limited.
1.1.4. Rats. A glaucoma rat model, induced by topical ap-
plication of dexamethasone, was also developed to study the
expression of myocilin. Although IOP was elevated after 2
weeks of treatment, the protein and mRNA levels of myocilin
in the TM and around Schlemm’s canal in the treated eyes
were not diﬀerent from those of the controls suggesting that
myocilin may not be directly linked to ocular hypertension
[27].
Similartomice,ratshavemanyadvantages.Incontrastto
other nonprimate models, the rat shares similar anatomical
[97, 98] and developmental [99, 100] characteristics of the
anterior chamber, especiallyin the aqueous outﬂow pathway,
with the human. Therefore, results obtained from the rat
are expected to mimic changes that occur in the human. In
addition, there is reasonable IOP elevation as retinal and ON
changes are similar to those seen in humans. Also, reduction
of IOP in response to glaucoma medications has been des-
cribed but the medication eﬀects were not all identical to
thoseobservedinhumans[101].Furthermore,ratsareeasier
to maintain in the laboratory and similar to mice they enable
genetic manipulation and can be used in large numbers.
1.1.5. Zebraﬁsh. Transgenic teleost Danio rerio (zebraﬁsh)
models have been developed for studying glaucoma [102,
103]. The bug eye mutant that was developed by Simon et al.
shows RGC death and high IOP [28, 29]. The mutant
developsbuphthalmiashortlyaftersexualmaturationandan
average IOP of 32.9 ± 16.2mmHg compared to that in the
wildtype(14.7±3.6mmHg).Thismodelwasrecentlyusedin
a study that led to the identiﬁcation of a mutation in the low-
density lipoprotein receptor-related protein 2 (Lrp2) that is
important for myopia and other risk factors for glaucoma
[30]. The lrp2 mutant exhibited a phenotype that included
highIOP,enlargedeyes,decreasedretinalneurons,activation
of RCG stress genes, and ON pathology. Another zebraﬁsh
glaucoma model, the wdr36 mutant that was developed
by Skarie and Link, was used to characterize the wdr364 Journal of Biomedicine and Biotechnology
function [31]. This model, however, was only developed to
study the function of wdr36, as it did not show a typical
glaucoma phenotype [31].
T h ez e b r a ﬁ s hm o d e lh a sr e c e i v e da t t e n t i o nf o ri t s
usefulness in studying glaucoma and other human diseases
[104, 105] because of its short generation times and a well-
supported genomic infrastructure. It allows the combination
of forward and reverse genetic approaches in order to
identify critical genetic interactions required for normal and
pathological events. This model would be ideal for studying
developmental changes in glaucoma such as those occurring
in PCG. It is easily adapted to laboratory settings and can
be maintained in a relatively small space. The ﬁsh typically
reaches sexual maturity in 3 to 4 months, and a breeding pair
can produce more than 200 fertilized eggs per mating. Fertil-
ization is external, and the egg and embryo are transparent,
which makes it easy to visualize the changes with a regular
dissecting microscope. The ﬁsh develops quickly, and all
major organ systems are formed by 24hrs after fertilization.
Mutagenesis in zebraﬁsh is performed by gamma ray and
chemical approaches. The ﬁsh also enables haploid screens
and diploidization, transgenesis, and forward and reverse
genetic approaches which make it an attractive model for
genetic manipulations of the visual system.
1.1.6. Other POAG Models. Administration of glucocorti-
costeroids can lead to the development of ocular hyper-
tension and POAG through a reduction in aqueous humor
outﬂow [106, 107]. Models using steroid-induced ocular
hypertension have been developed in many animals such
as rabbits, bovine, and sheep [32–34, 38–42]. A topical
application of prednisolone acetate induced IOP elevation
in 100% of bovine and sheep (from 16-17mmHg to 30–
35mmHg and from 11.2mmHg in to 23.2mmHg in bovine
and sheep, resp.). IOP in these animals returned to normal
when the treatment was discontinued. In rabbits, injection
of betamethasone subconjunctivally or α-chymotrypsin into
the posterior chamber also resulted in elevated IOP that
lasted for 7 weeks [35–37]. The consistency and robustness
of the IOP response and the low cost of maintaining the
animals developed using steroids (rats, rabbit, sheep, and
cows) compared to primates are all advantages of this model.
However, the prolonged topical corticosteroid treatment
required to achieve glaucoma can cause signiﬁcant adverse
eﬀects such as cataracts and corneal ulcers.
Avians. Light induced avian models of POAG have also been
described [43, 44]. IOP in these models appeared to be
responsive to several antiglaucoma drugs [45]. At 8-9 weeks
of age, the chicks had signiﬁcantly enlarged eyes and an IOP
that was slightly lower (13.79 v. 16.46mmHg; P<0.05).
At this age, the aqueous outﬂow was markedly reduced but
no change in aqueous inﬂow could be demonstrated. By 18
to 20 weeks the glaucomatous eyes were further enlarged
and the IOP was higher (mean IOP 29.85 v. 22.27mmHg;
P<0.05). Birds may be easy to handle in the laboratory and
are not expensive. This model could be potentially valuable
for studying the eﬀect of glaucoma medications on IOP.
1.2. Primary Angle Closure Glaucoma (PACG). Similar to
POAG,PACGischaracterizedbyelevatedIOP,damagetothe
ON, and visual ﬁeld loss. The iris in PACG obstructs the TM,
whereas in POAG the TM is open and unobstructed [108].
There are several animal models that have been developed
for the study of PACG (Table 1), some of these are congenital
such as dogs and turkeys, and some are induced such as mice
and rats.
1.2.1.Dogs. GlaucomaindogshasbeenidentiﬁedinBeagles,
Cockers, Wirehaired Fox Terrier, Sealyham Terriers, and
Basset Hounds [46–51] and was described in the late 1960s
by veterinary ophthalmologists. Glaucomain most species of
dogs is of the closed angle type. Dogs may also have con-
genital, primary, or secondary glaucoma [52]. It is a rare
condition and is caused by abnormalities in the aqueous
humor outﬂow pathways and mimics congenital glaucoma
in humans. Puppies generally present young (3–6 months of
age) with an acute onset of buphthalmia and corneal edema
with IOP reaching about 40mmHg at 18 months. It may
be unilateral and bilateral and may be associated with other
ocular anomalies [53]. Since the disease is rare in dogs and
the genotype and phenotype of glaucoma have not been well
characterized, this model has not been used to study angle
closure or congenital glaucoma.
1.2.2. Turkeys. An inherited eye disease leading to secondary
angle closure glaucoma was also described in a slate line
of domestic turkeys (Meleagris gallopavo) [54]. The disease
was progressive and the model demonstrated buphthalmia,
low-grade aqueous cell, and ﬂare associated with progressive
posterior synechiae formation resulting in papillary block
andirisbombe.IOPinthismodelwassigniﬁcantlyincreased
and was associated with an increase in corneal diameter. This
modelisgoodforstudyingangleclosureglaucoma;however,
its availability may be limited.
1.2.3. Mice. Genetically manipulated Vav2/Vav3-deﬁcient
mice were also described and found to have elevated IOP,
which eventually manifests as buphthalmos [61]. Loss of
Vav2 and Vav3 expression in these mice is associated with
changes in the iridocorneal angle, which leads to chronic
angle closure. The elevation of IOP is accompanied by se-
lective loss of RGCs and optic nerve head (ONH) excavation.
The characteristics that make this model useful for glau-
coma research are as follows: (1) the elevated IOP occurs
spontaneously in these mice and does not require the ocular
manipulationnecessaryininducedmodels,(2)thefrequency
o ft h eo c u l a rp h e n o t y p ei sh i g ha n do n s e to c c u r sa ta
relatively young age, and (3) ocular hypotensives commonly
used to treat human glaucoma show eﬃcacy in lowering IOP
in this model. The most signiﬁcant advantage of this mouse
glaucoma model is that the deleted genes, Vav2 and Vav3, are
well-focused targets that have been studied for over 20 years,
providing a useful starting point for further investigation
of the potential molecular mechanisms underlying this
phenotype.Journal of Biomedicine and Biotechnology 5
1.2.4. Additional PACG Models. A wide variety of rat and
mouse models have been developed to study the eﬀect of
elevated IOP on the ON and RGC degeneration. Though
these models were primarily developed to study retinal
IOP-relatedposteriorsegmentdamage,thehistopathological
examination showed varying degrees of angle closure. IOP
elevation has been induced by a number of techniques
that include the use of hypertonic saline injection into the
episcleral veins, cauterization or ligation of episcleral veins,
or laser photocoagulation of the perilimbal region.
(1) Rats. Episcleral vein saline injections of Brown Norway
rats resulted in sustained IOP elevations after 4 weeks in
45% of rats with 35% developing sustained elevations after
subsequent injections [55]. Of those having sustained ele-
vations, the mean IOP change from baseline ranged from 7
to 28mmHg. IOP change of 10 to 20mmHg for more than
3w e e k so rg r e a t e rt h a n2 0m m H gf o ro v e r1w e e kr e s u l t e d
in total involvement of the ON with occasional axons that
appeared morphologically normal. Electron micrographs of
eyes from this model showed axons within damaged nerves
which were frequently swollen associated with accumulation
of vesicles, dense bodies, and swollen mitochondria provid-
ing histological evidence of glaucoma. Additional models
using ﬂuorescent polystyrene microbeads and hyaluronic
acid injections have also been developed [56, 57]. These
modelsshowedasigniﬁcantIOPelevationandglaucomatous
damage in the retina. Wistar rats injected with a solution
of microbeads demonstrated an IOP of 29.7mmHg that
remained stable for 13 days and resulted in an axon density
that was 16% lower than that in the control groups [56].
Wistar rats receiving weekly injections of hyaluronic acid
had elevated IOP in the low 20s for the duration of the 10
weeks. Eyes enucleated after 10 weeks showed signiﬁcant loss
of RGCs [57].
When cauterization of episcleral veins of Wistar rats was
used [58], an IOP elevation from 13.2mmHg to 53mmHg
was noted. There was an increase of 2.3-fold above the mean
normal IOP at 2.5 months, whereas ligation of the episcleral
veins increased IOP from 20.2mmHg to 27.7mmHg after
one week and IOP elevation persisted for 7 months in 40.8%
of animals [59]. Further ligation was needed in 59.2% of ani-
mals for induced persistent IOP elevation. At 24 weeks there
was a 35% reduction in the RGC number compared with
control retinas. Intracameral India Ink injection resulted in a
dark circle along the circumference of the limbus. Translim-
bal photocoagulation of the darkened area raised IOP to
greater than 25mmHg after 3 laser treatments; however,
further laser treatments were necessary to maintain IOP >
20mmHg during the course of the study. The thickness of
the nerve ﬁber layer decreased in the glaucomatous eyes and
the surfacenerve ﬁber layerand prelaminar region of the ON
were considerably atrophic. Another study using translimbal
photocoagulation with a diode laser (with laser settings of
0.7 seconds and 0.4 Watts) that was aimed at either the TM
and episcleral veins or only the TM of Wistar rats yielded an
elevated IOP and subsequent glaucomatous damage which
included RGC loss and abnormal outﬂow channels in the
anterior chamber [60]. Peak IOP was 49.0mmHg in the
combination group and 34mmHg in the TM only group.
IOP remained elevated for 3 weeks for both methods and
there was axonal loss with both methods.
As mentioned previously, rats are easy and more eco-
nomical to maintain, and a large number can be treated in
one day by one person reducing the cost associated with ad-
ditionalpersonnel.However,similartootherinducedanimal
models, the technique may need multiple sessions to achieve
IOP elevation. Although IOP elevation is achieved, the
response to induction of glaucoma may be inconsistent. The
hypertonic saline model is likely to be the most consistent
model but is technically diﬃcult to perform and has mainly
been used in Brown Norway rats. The IOP elevation in all
these models is sustained for a period of 2–6 weeks.
(2) Mice. Other mouse models that have been developed to
study PACG included those developed by photocoagulation
of the episcleral vessels [62, 63, 109] and episcleral vein
cauterization [64]. These models exhibited elevated IOP for
up to 4 weeks, loss of RGCs, and damage of RGC axons.
Translimbal-photocoagulation-treated eyes of Black Swiss
mice reached a maximum IOP of 39.6mmHg with IOP ele-
vation being statistically signiﬁcant compared with controls
for up to 6 weeks [109], whereas in photocoagulation of
episcleral- and limbal-vein-treated Albino CD1 mice eyes
had doubling of their IOP within 4 hours [62]. IOP in these
models remained stable through the second postoperative
day (27.6mmHg) but returned to baseline after one week.
At day fourteen after treatment, there was a 42% loss of
RGCs.WhenC57BL/6Jmiceweretreatedinasimilarfashion
as described previously, during the ﬁrst four weeks after
laser treatment, the mean IOP was 20mmHg compared
with 13mmHg before treatment. Two weeks after laser
photocoagulation, the percentage of RCG lost in treated
eyes of these mice with elevated IOP compared to untreated
controls was about 17% and at 4 weeks, and the death rate
was 22.4% [63]. Using ﬂuorescent polystyrene microbeads
injectioninC57BL/6miceaswell,aconsistent30%elevation
in IOP that persisted for more than 3 weeks was achieved
using 1 single injection [56].
(3) Rabbits. Rabbit models for angle closure glaucoma were
also created by either water loading [65, 66] or argon laser
energy applied to the TM [67–69]. Both pigmented and
albino rabbits were used in these studies. Although elevated
IOP and buphthalmia were achieved in these animals, these
models all had drawbacks. For example, in the water loading
models, the damage produced included the whole eye and
the IOP rise was of insuﬃcient duration (1hr) and caused
selectivelossofRGCs.Inthelaser-inducedglaucomamodels,
the IOP elevation lasted for a few weeks but it was hard
to achieve a successful model because of the structure
of the iridocorneal angle, which is diﬀerent from that of
humans. The longest IOP elevation was reported in the α-
chymotrypsin-injected models.
1.3. Primary Congenital Glaucoma. Primary Congenital
Glaucoma (PCG) is an autosomal recessive disease caused6 Journal of Biomedicine and Biotechnology
by an abnormal development of the anterior chamber
angle. PCG has been linked to several genetic loci. CYP1B1
and LTBP2 are the only genes in which mutations are
currently known. However, the role that these genes play
in the pathophysiology of PCG and development of the ante-
rior chamber is not known. An assortment of spontaneous
glaucoma models has been described in diﬀerent animal
species (Table 1). These included rabbits, dogs, monkeys,
mice, rats, cats, and albino quails. The study of these models
has provided valuable information on the pathophysiology
of glaucoma as it relates to changes in the anterior chamber
angle, the ON, and the retina but the mechanisms leading to
these changes are still elusive.
1.3.1. Rabbits. Spontaneous Congenital Glaucoma in rabbits
was ﬁrst described in 1886 by Schloesser [70]. However,
research with this model did not advance until the 1960s
when Kolker et al. [73], Hanna et al. [72], and Fox et al. [71]
described a group of albino New Zealand rabbits that spon-
taneously exhibited congenital abnormalities in the develop-
ment of the anterior chamber. The abnormalities included
loss or compression of the iris pillars (pectinate ligaments)
and posterior displacement or poor development of the
aqueous plexus. Additional ﬁndings include dilated or com-
pressed intertrabecular spaces, disorganization of trabecular
lamellae, decreased trabecular endothelial cells, and a loss of
trabecular endothelial cell-to-cell associations. Others have
reported the replacement of the angular meshwork (the tra-
becular meshwork-like structure in rabbits) with abundant
extracellular matrix (ECM), basal-lamina like material, and
unidentiﬁed round cells just beneath the aqueous plexus
[74, 75]. The anterior chamber angle dysgenesis in the rabbit
appearstobesecondarytoanalterationinthediﬀerentiation
and maintenance of the structural integrity of the angular
meshwork. Some of these changes bear resemblance to
angle changes seen in PCG in humans [72]. The interest
in studying this model decreased in the 1990s when other
genetic models of glaucoma became available.
Many studies have indicated that glaucoma in rabbits is
most likely autosomal recessive with incomplete penetrance
(semi lethal) [72]. It typically manifests in the ﬁrst 6 months
and is associated with variable IOP elevation, enlarged
cloudy corneas, and elongated globes. The outﬂow facility
is decreased, suggesting a defect in the outﬂow pathway,
whichcorrelateswiththereportedhistologicalﬁndings.RGC
loss and cupping of the optic nerve were also observed in
these rabbits. The phenotypic similarities between rabbits
and human patients with congenital glaucoma include the
age of onset, IOP elevation, and buphthalmia. In addition,
the rabbit eye is also relatively large, which makes it a good
model for eye research. However, there are some limitations
that make this animal unsuitable for glaucoma research.
These include diﬀerences in the structure of the trabecular
meshwork and aqueous outﬂow pathways between the
human and the rabbit making it diﬃcult to make direct cor-
relations between the developmental changes in the anterior
chamber angle in both species. In addition, IOP levels
in the buphthalmic rabbit were found to decrease with
age. IOP was found to be comparable to normal (18–
20mmHg) until about 5 months of age, followed by in-
termittent elevation into the 30mmHg range. A decrease in
outﬂow facility precedes the elevation of IOP. The IOP eleva-
tion among animals is variable (20–30mmHg) up to about
18 months of age; then it decreases to near the normal range
between 24 and 48 months. The cause of IOP reduction to
normal levels despite decreased outﬂow facility is unclear.
The genome sequence of the rabbit was recently made
available at http://www.ncbi.nlm.nih.gov/projects/genome/
guide/rabbit/. This will help identify the genetic defects that
cause glaucoma. The biggest disadvantage of this model is
its limited availability from commercial vendors. This model
has recently been used to study the protein changes in
the aqueous humor and has provided valuable information
about proteomics and the histopathological changes seen
in the anterior chamber of this rabbit, although a CYP1B1
mutation could not be identiﬁed in this model [110].
1.3.2. Rats. Congenital glaucoma in rats was ﬁrst described
in 1926 by Addison and How [76], and in 1974, Young et al.
also reported a spontaneous occurrence of buphthalmos in a
colony of WAG inbred rats [77]. The condition in the latter
appearedtobeinheritedbutnocompletelysatisfactorymode
of inheritance was given. These reports were followed by
another one in 1975 by Heywood [78]. Recently, an RCS-
rdy− rat model that develops glaucoma spontaneously was
also described [78, 79]. The mutant animals had either a
unilateral or bilateral enlargement of the globes with an IOP
that ranged from 25 to 45mmHg, as compared to control
values of 12–16mmHg. The IOP increased signiﬁcantly with
age to reach a value of 35 ± 7.3 at 12–18 months of age. The
animals also had decreased number of RGCs with age as
well as atrophic ONHs. The anterior chamber was narrow
and the iridocorneal angle was open. These rats were used
in other studies in glaucoma research and yielded valuable
information about RGC loss [111].
1.3.3. Cats. Feline glaucoma is a rare condition. It has been
described in Burmese cats [80], domestic cats [6], and Sia-
mese cats [21, 81]. Examination of the Siamese cats revealed
bilateral mild-to-moderate buphthalmos and moderate ele-
vation in IOP, which was as high as 31.6mmHg. Clinical
features identiﬁed in these cats were similar to those seen in
human PCG, though details such as IOP levels and clinical
course were not described in these reports. Structurally,
these cats had prominent, elongated ciliary processes, Haab’s
striae, and lens subluxation. Gonioscopic examination re-
vealed open or slightly narrowed iridocorneal angles, with
mild pectinate ligament dysplasia and sparse prominent iris
processes. Histological examination of Burmese cat eyes
revealed loss of RGC, corneal edema, and multifocal breaks
in Descemet’s membrane [112]. Similar to rabbits, the cat
eyes are relatively larger making them attractive for use in
glaucoma research. However, no further reports were pub-
lished describing clinical, pathological, and genetic charac-
terization of the disease in cats.Journal of Biomedicine and Biotechnology 7
1.3.4. Mice. A knockout model with Cyp1b1 has also been
developed to simulate PCG where CYP1B1 mutations are the
predominant cause of PCG in humans in some populations
[82]. Cyp1b1-deﬁcient mice exhibit abnormalities in their
ocular drainage structure and TM that are similar to those
reported in human PCG patients [83]. However, other stud-
ies generated a Cyp1b1-null mouse that revealed no evidence
of glaucoma, and the animals were not blind [84]. A
mouse model with mutations in both Cyp1b1 and Tyr
(tyrosinase) was also developed. Studies using this model
showed that the anterior segment developmental pathway
involves a tyrosinase and that the Tyr mutation modiﬁes the
phenotype associated with inheritance of mutant orthologs
of Cyp1b1 and Foxc1, which both have been shown to cause
PCG in humans [85]. Although results are contradictory,
studies using this model could lead to understanding the
abnormalities seen in the ocular drainage and the structure
of the TM. Similar to the buphthalmic rabbit described
previously, CYP1B1 mutation could be speciﬁc to the human
PCG only which makes this model and other PCG animal
models not suitable for studying the genetics in this disease.
1.3.5. Albino Quails. The albino quail model of glaucoma
(al mutant) was described in 1986 by Takatsuji et al. [86].
The al mutation is sex-linked semilethal recessive of known
penetrance. The gene mutation has not been described.
The bird exhibited enlargement of the eye, RGC degener-
ation, cupping of the optic disc, and cataract with retinal
histopathological features similar to those in animals with
experimentally induced or spontaneous glaucoma. Loss of
RGCs was similar to human [87]. The al mutant quails show
signiﬁcantly higher IOP at 6 months of age. The iridocorneal
angle is initially open but eventually closes in later stages of
the disease [86]. The mutant bird would be a good model
to study glaucoma, as it is easy to maintain and to handle
in a laboratory. However, the cornea of these birds is very
small and IOP measurement may be challenging, although a
tonopen can be used. In addition, availability of the albino
quail is also limited.
1.4. Other Types of Glaucoma
1.4.1. Normal Tension Glaucoma. Normal Pressure or Nor-
mal Tension Glaucoma (NTG) is a condition where the clini-
calfeaturesare largelyidentical to those seen in POAG except
the IOP, which, in aﬀected patients, is below the statistically
normal upper limit (21mmHg). The pathophysiology of
RGC degeneration and ON damage in NTG remains unclear.
A number of factors have been implicated as potential
mechanisms of RGC degeneration. Some of these include
poor blood ﬂow to the ON, genetic mutations, and vascular
spasm [113–115]. To explore the possible pathways of RGC
degeneration, genetically modiﬁed mice with normal IOP
have been utilized as models of NTG as described below.
Because glutamate excitotoxicity and oxidative stress
havebeenimplicatedinRGCdeath,micedeﬁcientintheglu-
tamatetransportergenes Glast or Eaac1havebeendeveloped
as models for normal tension glaucoma. These mice demon-
strateRGCandONdegenerationwithoutIOPelevation[88]
suggesting that these transporters play important roles in
preventing RGC degeneration by keeping the extracellular
glutamate concentration below the neurotoxic level and
maintaining the glutathione levels in M¨ uller cells by synthe-
sizing and transporting glutamate into the cells. Glutamate is
the substrate for glutathione synthesis. This model was used
to investigate ASK1 deﬁciency on neural cell death [116].
ASK1 is a mitogen-activated protein kinase (MAPK) kinase
kinase and has an important role in stress-induced RGC
apoptosis.TheauthorsfoundthatlossofASK1hadnoeﬀects
on the production of glutathione or malondialdehyde in
the retina or on IOP. Tumor-necrosis-factor-(TNF-) induced
activation of p38 MAPK and the production of inducible
nitric oxide synthase were suppressed also in ASK1-deﬁcient
M¨ uller glial cells and RGCs which suggested that ASK1
activation is involved in NTG.
1.4.2. Autoimmune Glaucoma. Several reports have sug-
gested that an autoimmune response is one possible mech-
anism of RGC degeneration in normal pressure glaucoma
[117]. To test this hypothesis, some studies have examined
serum samples from glaucoma patients to look for auto-
antibodies and have found increased levels of heat shock
protein 27 (HSP27) and heat shock protein 60 (HSP60).
HSP27 and HSP60 immunization in the Lewis rat induced
RGC degeneration and axonal loss 1–4 months later in a
pattern similar to human glaucoma [89], suggesting the role
of these proteins in the development of glaucoma. The mod-
els also showed IOP-independent RGC loss and changes in
serum antibody patterns [90]. Experimental autoimmune
glaucoma oﬀers a valuable tool to examine the diverse roles
of the immune system in glaucoma. It may also facilitate
the identiﬁcation of treatment strategies to prevent pressure-
independent RGC degeneration as it may occur in select
patients with glaucoma. However, depending on the animal
used, limitations can be encountered such as the size of the
eye, the cost of the animal, and the anatomical similarities of
the animal’s eye to that of the human.
1.4.3. Pigmentary Glaucoma. The DBA/2J mouse, which
develops a progressive increase of IOP, was recognized in
1978 [118]. The glaucoma in this strain is caused by iris
abnormalities related to recessive mutations in two genes,
glycosylated protein nmb (Gpnmb) and tyrosinase-related
protein 1 (Tyrp1)[ 91, 92]. Both mutations show incomplete
penetrance. Therefore, only about 70% of animals develop
glaucoma [93]. The mechanism of glaucoma is related to iris
atrophy, pigment dispersion, and development of peripheral
anterior synechiae leading to angle closure. IOP elevation in
the DBA/2J mouse is seen at 8 months of age and remains
until death. The mouse develops pigment dispersion which
precedes iris atrophy, anterior synechiae, and elevated IOP.
These changes are accompanied by retinal and ON changes
consistent with glaucoma. The disease progresses with in-
creasing age similar to glaucoma in humans [92, 118].
However, there appears to be a closed angle component to8 Journal of Biomedicine and Biotechnology
the glaucoma unlike in humans where pigmentary glaucoma
is of an open angle form. Although this model has been
extensively studied, there is one limitation that makes this
model not ideal for studying glaucoma: The elevated IOP
phenotype is not primary, but secondary due to the systemic
pigment dispersion syndrome with the associated mutations
in the Gpnmb and Tyrp1 loci [91, 92]. In addition, mice with
spontaneous glaucoma other than the DBA/2J, such as the
DBA/2andDBA/2NNia,arediﬃculttoobtaincommercially.
2. Conclusion
This paper describes most of the animal models utilized
in glaucoma research to date. These animal models have
provided valuable information about certain aspects of the
disease process but the search for models that address
knowledgegapsinspeciﬁcformsofglaucomamustcontinue.
Thevalidityofeachofthesemodelsdependsuponthedegree
ofsimilaritytothehumanconditionaswellasconsiderations
of the model being economical and practical. Since the
mechanisms of glaucoma diﬀer among animal models, data
obtained from a particular model should not be generalized
and should be interpreted within the context of that model.
The animal model used should be selected based on the
experimental needs and the hypothesis being tested. For
example, genetically induced models might be preferable to
investigate the eﬀects of elevated IOP on the ocular tissues
over prolonged periods without the superimposed eﬀects of
experimental procedures or inﬂammation whereas sponta-
neously occurring large animal models such as monkeys,
dogs, rabbit, and the recently described pig [8]o ﬀer a unique
opportunity to collect data by using instrumentation identi-
cal to that used in human patients with glaucoma. Exper-
imentally induced models have the advantage of studying
some of the changes in glaucoma over a short period of time.
However, sophisticated equipment and trained personnel to
induce glaucoma are often needed. In addition, glaucoma
induction can be somewhat unpredictable. These models
may be useful in testing responses to medications. It is likely
that genetic models developed to address speciﬁc hypotheses
will provide valuable information on the pathophysiology of
the various types and aspects of glaucoma and potentially
lead to the discovery of new therapeutic targets.
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